Article Details
Retrieved on: 2021-03-26 12:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
While most of Boehringer Ingelheim's revenues come from its own portfolio of human and animal therapeutics, Boehringer Ingelheim's biopharma ...
Article found on: bioprocessintl.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here